Financings in Brief: Aastrom Biosciences
This article was originally published in The Gray Sheet
Executive Summary
Aastrom Biosciences: Company plans a secondary offering of 1.5 mil. shares of common stock. Net proceeds will help fund clinical trials of Aastrom's cell production system, designed for use in large scale ex vivo production of a variety of therapeutic cells ("The Gray Sheet" May 26, I&W-11), as well as R&D of other product candidates, and provide working capital. Cowen & Company is managing the deal...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.